After 4 weeks, 57% of patients exhibited serologic responses to NY-ESO-1, one of the 21 patients developed antibodies to GAGE7, and four of the patients exhibited reactivity to XAGE and MAGE-C2, suggesting that immunity to CTAs can be easily induced by lung cancer cell lysate vaccine (98). Here, CTAG1B is linked to lung cancer.